ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer
Improvement seen in progression-free survival with add-on pembrolizumab in gastroesophageal junction adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.